Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 19/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 17/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 17/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | MYLK | Q15746 | 1/20 | 0.41 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802855 | 1.00 | MAPK8 (0.46) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL19665495 | 0.95 | MAPK9 (0.43) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL29802576 | 0.95 | MAPK9 (0.43) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL19665541 | 0.94 | MAPK9 (0.43) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL29802493 | 0.94 | MAPK9 (0.43) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL21385847 | 0.91 | MAPK8 (0.46) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL19665666 | 0.90 | MAPK9 (0.41) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL29802898 | 0.90 | MAPK9 (0.41) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL19665638 | 0.89 | MAPK9 (0.42) | MAPK8MAPK9MAPK10MAPK14EGFR | |
| SCHEMBL29802863 | 0.89 | MAPK9 (0.42) | MAPK8MAPK9MAPK10MAPK14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | claimed |
| CN-109563095-B | Animal and human antimalarial agents | 细胞基因公司 | 2021-10-29 | — | — | CN | claimed |
| US-10420771-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2019-09-24 | — | — | US | claimed |
| EP-3464287-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | Celgene Corporation (US) | 2019-04-10 | — | — | EP | claimed |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2018-10-04 | — | — | US | claimed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | claimed |
| WO-2017210399-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | claimed |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | claimed |
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3464287-B1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344554-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2022-05-31 | — | — | US | disclosed |
| CN-109563095-B | Animal and human antimalarial agents | 细胞基因公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20200330469-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORP (US) | 2020-10-22 | — | — | US | disclosed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016436-B2 | Animal and human anti-malarial agents | CELGENE CORPORATION (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2017210399-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017210399-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330469-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | MAPK8 3431/4885MAPK9 3844/4885MAPK10 3792/4885 |
| US-20170348316-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, NUDT1, UMPS | MAPK8 3532/4885MAPK9 3736/4885MAPK10 3567/4885 |
| US-10420771-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | MAPK8 3423/4885MAPK9 3838/4885MAPK10 3811/4885 |
| US-10016436-B2 | Animal and human anti-malarial agents | HPRT1, NUDT1, UMPS | MAPK8 3532/4885MAPK9 3736/4885MAPK10 3567/4885 |
| US-11344554-B2 | Animal and human anti-malarial agents | HPRT1, UMPS, PNP | MAPK8 3431/4885MAPK9 3844/4885MAPK10 3792/4885 |
| US-20180280398-A1 | ANIMAL AND HUMAN ANTI-MALARIAL AGENTS | HPRT1, UMPS, PNP | MAPK8 3431/4885MAPK9 3844/4885MAPK10 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.